UCN-01 and Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors

Phase 1 Completed City of Hope Medical Center National Cancer Institute (NCI) · collab

Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of UCN-01 and cisplatin in treating patients who have advanced or metastatic solid tumors.

Timeline

Start: 2001-03
Primary completion: 2005-01
Completion: 2008-06

Publications

Results Lara PN Jr, Mack PC, Synold T, Frankel P, Longmate J, Gumerlock PH, Doroshow JH, Gandara DR. The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial. Clin Cancer Res. 2005 Jun 15;11(12):4444-50. doi: 10.1158/1078-0432.CCR-04-2602.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cisplatin	Other / unclassified	20 mg/m2	Intravenous
Subject	Cisplatin	Other / unclassified	30 mg/m2	Intravenous
Subject	Cisplatin	Other / unclassified	45 mg/m2	Intravenous
Subject	Cisplatin	Other / unclassified	60 mg/m2	Intravenous
Subject	Cisplatin	Other / unclassified	75 mg/m2	Intravenous
Subject	UCN-01	Small molecule	45 mg/m2	Intravenous

UCN-01 and Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors

Summary

Timeline

Publications

Drugs

Indications